Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.02.018
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study

British Journal of Dermatology
DermatologyMedicine
2018English

The Experience of Pain and Redness in Patients With Moderate to Severe Plaque Psoriasis

Journal of Dermatological Treatment
Dermatology
2015English

Pss15 - Budget Impact Analysis of Apremilast in Patients With Moderate-To-Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

New Polymorphisms Associated With Response to Anti-TNF Drugs in Patients With Moderate-To-Severe Plaque Psoriasis

Pharmacogenomics Journal
Molecular MedicineGeneticsPharmacology
2016English

Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis

Biopharmaceutics and Drug Disposition
MedicinePharmacologyPharmaceutical Science
2018English

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology
DermatologyMedicine
2020English

IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-To-Severe Plaque Psoriasis Patients

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy